LWMI
CORT icon

Legacy Wealth Management (Idaho)’s Corcept Therapeutics CORT Stock Holding History

Legacy Wealth Management (Idaho)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59
Closed -$2.38K – 344
2026
Q1 		$2.38K Sell
59
-28
-32% -$1.05K ﹤0.01% 747
2025
Q4 		$3.03K Buy
87
+70
+412% +$5.5K ﹤0.01% 612
2025
Q3 		$1.41K Hold
17
– – ﹤0.01% 586
2025
Q2 		$1.25K Sell
17
-11
-39% -$798 ﹤0.01% 570
2025
Q1 		$3.2K Hold
28
– – ﹤0.01% 469
2024
Q4 		$1.91K Buy
28
+11
+65% +$576 ﹤0.01% 505
2024
Q3 		$960 Buy
+17
New +$604 ﹤0.01% 550

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legacy Wealth Management (Idaho)'s CORT Position: Q2 2026 in Review

Legacy Wealth Management (Idaho) sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 59 shares — an estimated $2.38K sold.

Legacy Wealth Management (Idaho) first reported a position in CORT in Q3 2024 and held it in 7 quarters. The position peaked at $3.2K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Legacy Wealth Management (Idaho) reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 59 Corcept Therapeutics shares in Q2 2026, an estimated $2.38K.
  • Legacy Wealth Management (Idaho) first reported a position in Corcept Therapeutics in Q3 2024 and held it in 7 quarters.
  • Legacy Wealth Management (Idaho)'s Corcept Therapeutics position peaked at $3.2K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q2 2026, filed 13 Aug 2026.